Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's EBITDA?
- Ultragenyx Pharmaceutical (RARE) reported EBITDA of -$67M in Q2 2026.
- How has Ultragenyx Pharmaceutical's EBITDA changed year-over-year?
- Ultragenyx Pharmaceutical's EBITDA increased by 32.3% year-over-year, from -$99M to -$67M.
- What is the long-term trend for Ultragenyx Pharmaceutical's EBITDA?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's EBITDA has grown at a 7.9% compound annual growth rate (CAGR), from -$368.5M to -$500.17M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Ultragenyx Pharmaceutical's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude